In light of the evolving landscape of veterinary medicine, the Committee for Veterinary Medicinal Products (CVMP) Safety Working Party (SWP-V) has announced its comprehensive work plan for 2026. Chaired by C. Bergman and adopted by the CVMP on December 2025, the plan pivots on key business priorities. It features an organized itinerary of meetings and workshops, specified direction on product assessments, development of essential guidance documents, and cooperation with the European Food Safety Authority (EFSA). With an eye on advancing both consumer and pharmaceutical standards, the SWP-V is setting a formidable agenda for addressing the safety issues facing veterinary products. This strategized approach comes at a time when stakeholders in the veterinary field are anticipating significant regulatory shifts aimed at consolidating consumer safety and enhancing efficacy in veterinary care.
Strategic Meeting Schedule
This upcoming year, the SWP-V has planned three plenary meetings set for March, June, and November 2026, combining both virtual and face-to-face formats. These meetings aim to bring together the Chairperson, twelve members, and potential ad-hoc participants. Additionally, drafting and expert group meetings will take place as required, providing important supplementary discussions to the plenary sessions. Training workshops tailored to enhance understanding of emerging topics such as the Maximum Residue Limits (MRL) will also be part of the 2026 commitments.
Guidelines and Product Assessments
The committee has lined up revisions of existing guideline documents, particularly focusing on user safety for both topical and pharmaceutical veterinary medicinal products. Collaborating with the 3Rs Working Party (3RsWP), these updates will incorporate modern standards on dermal absorption and risk mitigation measures, drawing insights from the latest European standards and scientific opinions. New guidelines addressing consumer safety concerning immunological active substances remain a high priority, reflecting the commitment to safeguarding public health.
– The revision of dermal absorption guidelines involves addressing developments in absorption factors and exposure calculations.
– Guidelines on genotoxicity testing highlight waivers for in vivo studies using EFSA’s 2011 strategies.
– Collaborative efforts with the Codex Alimentarius aim to establish EU standing on safety of drug residues.
By contributing to regulatory activities and cross-party collaborations, SWP-V seeks to harmonize risk assessment approaches while endorsing novel therapies. Support for assessor training and participation in creating a common framework for consumer exposure analysis are pivotal parts of this year’s goals. The efforts ensure that the methodologies facilitate safe and effective veterinary practices globally.
Positioning itself at the forefront of veterinary medicine safety and regulation, the SWP-V plans for 2026 underline a committed path to robust scientific assessment and regulatory innovation. Recognizing the ever-changing dynamics of veterinary science and pharmaceuticals, these plans reflect a collective ambition to confront the challenges of contemporary veterinary medicine. The actionable outputs and targeted efforts will not only enhance the faith in veterinary products but also align with high safety standards for consumer and animal welfare. The collaboration with internal and external bodies underlines a strategic approach, fostering a globally recognized framework for sustainable and safe veterinary practices. As such, the work plan not only paves a path forward but also raises the bar for veterinary health products and their approval processes.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
